TABLE 2.

Cycles, Escalated Dose of Olaparib, and DLT

Patient	Cycles (n)	Reached dose of olaparib	DLT	Other reason for hampered escalation
Cohort 1
1	2	100 mg BID		Progressive disease after 2 cycles^*
2	4	300 mg BID
4	4	200 mg BID		Abdominal pain G1^†
5	2	100 mg BID		Progressive disease after 2 cycles^*
6	4	300 mg BID
7	2	50 mg BID		Noncompliant^*
8	4	100 mg BID		Fatigue G2, nausea G2, loss of appetite G2
9	4	300 mg BID
10	4	300 mg BID
11	4	300 mg BID^‡	Thrombocytopenia G3
12	4	300 mg BID
Cohort 2
13	4	300 mg BID^‡	Thrombocytopenia G3
14	3	100 mg BID		Thrombocytopenia G2
15	4	300 mg BID
16	4	300 mg BID^‡		Thrombocytopenia G2
17	1	0 mg		Carcinoid reaction on first ¹⁷⁷Lu infusion^*
19	2	200 mg BID		Progressive disease after 2 cycles^*
20	4	300 mg BID^‡	Thrombocytopenia G3

↵* Premature study discontinuation.
↵† Not escalated at cycle 1 because of abdominal pain G1, so did not reach 300 mg.
↵‡ Discontinued last cycle of olaparib.
G1 = grade 1; G2 = grade 2; G3 = grade 3.
Patients 3 and 18 were excluded from the study.